The Nasdaq delisting notice is a significant negative event for Nymox Pharmaceutical. It indicates that the company does not meet Nasdaq's listing requirements, which could lead to its shares being removed from the exchange. This can result in a decrease in the liquidity of the shares, making them harder to buy or sell, which is likely why the shares are trading lower.